About Inimmune
Inimmune is a pioneering biotech company dedicated to harnessing the innate immune system to treat and prevent disease. Our lead clinical program is a disease-modifying therapy for seasonal allergic rhinitis that targets TLR4 to reprogram the immune response against environmental allergens. Building on our expertise in immunomodulation, we are also advancing a pipeline that includes an oncology immunotherapy targeting TLR 7/8 and future clinical vaccine programs.
The Opportunity
We are seeking a Chief Medical Officer (CMO) to provide strategic and operational leadership and execution oversight of Inimmune’s innate immune focused clinical development programs, with indications in Allergy and Oncology. The ideal candidate should bring deep domain expertise in Immunology and Inflammation with experience in designing late-stage clinical trials in Allergy and Oncology preferred. Experience with vaccines and vaccine development is a plus.
Key Responsibilities
Clinical Development Strategy and Execution
Clinical Trial Operational Execution and Oversight
Regulatory Collaboration
Medical Affairs and key Stakeholder Engagement
Cross-Functional Collaboration
Portfolio Program Prioritization and Ongoing Program Support
Qualifications
Why Join Inimmune?
• Be part of the executive team that is bringing novel, disease-modifying therapies to patients
• Lead the clinical strategy of a growing biotech company with a groundbreaking approach to innate immunotherapy.
• Work alongside a passionate and innovative team dedicated to improving patients’ lives.
• Competitive salary, equity options, and comprehensive benefits package.
If you are a visionary clinical leader eager to shape the future of allergy treatment, we’d love to hear from you! Inimmune is an Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability, or protected Veteran status.
Inimmune is a biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of next generation vaccines and immunotherapeutics.